Pelthos Therapeutics opened higher at $9.45, compared with its previous close of $9.39. In the last trading session, the stock traded between $7.79 and $9.45. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 2 years ago in Pelthos Therapeutics is now worth
$ 48.99
Resulting in a loss of
$ 51.01 (51.01%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 6 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-1.31 (-13.91%)
Day High
$9.45
Day Low
$7.79
Day Open
$9.45
Prev Close
$9.39
Volume
1,23,673
1W Return
-21.48%
1M Return
-58.90%
3M Return
-71.89%
6M Return
-69.89%
1Y Return
-75.50%
Fundamentals
Market Cap ($ Mn)
32
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-258.68%
ROCE
-123.79%
EPS (TTM)
$-6.30
Investment Returns
1 Week
-21.48%
1 Month
-58.90%
3 Months
-71.89%
6 Months
-69.89%
9 Months
-63.35%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
7.4
Sep 25
9.4
Dec 25
10.9
Mar 26
15.6
Jun 26
Updates
12Nov
Pelthos Therapeutics Q3FY26 Results: Net revenue rises 114% YoY to $15.2 million
Net revenue for Zelsubi rose 114% YoY to $15.2 million in Q3FY26. Net loss narrowed to $7.9 million from $23.4 million in Q2FY26. Formulary coverage expanded to 70% of commercial lives and 100% of Medicaid lives. Acquisition of Castle Creek Biosciences announced to add DEFI gene therapy candidate. SG&A expenses decreased 25% QoQ to $18.8 million.
Pelthos Therapeutics reported Q2 2026 sales of $15.603 million, beating estimates, but missed EPS expectations with a loss of $(6.62) per share versus an estimated $(3.05). Net product revenue rose 45% to $15.4 million driven by Zelsuvmi demand, though SG&A expenses surged 31% due to milestones. The company holds $24.2 million in cash.
3mo ago
3Aug
Pelthos Therapeutics Q2 Results: Earnings call set for Aug 13
Pelthos Therapeutics Inc. will release Q2 2026 earnings on August 13, 2026, accompanied by an investor call at 8:30 a.m. ET. The company continues to advance its portfolio of topical treatments for skin infections, led by ZELSUVMI.
3mo ago
1Jul
Pelthos Therapeutics joins Russell 3000E Growth and Microcap Indexes
Pelthos Therapeutics Inc. was added to the Russell 3000E Growth Benchmark, Russell Microcap, and Russell Microcap Growth Benchmark Indexes effective when the US market opened on June 29. The inclusion is part of the 2026 Russell indexes reconstitution, which captures up to the 4,000 largest US stocks as of April 30. Membership in these indexes is determined primarily by objective, market-capitalization rankings and style attributes.
